Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 2163-8306|6|12|804-813

ISSN： 2163-8306

Source： Cpt: Pharmacometrics & Systems Pharmacology, Vol.6, Iss.12, 2017-12, pp. : 804-813

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

By Hasegawa Mayumi  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 38, Iss. 6, 2011-12 ,pp. : 803-832

Springer Publishing Company

Access to resources Recommend Favorite

Simvastatin inhibits cytokines in a dose response in patients with rheumatoid arthritis

By Pereira Michelly   Cardoso Pablo   Rocha Laurindo   Rêgo Moacyr   Gonçalves Sayonara   Santos Flaviana   Galdino-Pitta Marina   Dantas Andréa   Duarte Ângela   Pitta Maira  

Inflammation Research, Vol. 63, Iss. 4, 2014-04 ,pp. : 309-315

Springer Publishing Company

Access to resources Recommend Favorite

Durability and Rapidity of Response to Anakinra in Patients with Rheumatoid Arthritis

By Michael H. Schiff  

Drugs, Vol. 64, Iss. 22, 2004-01 ,pp. : 2493-2501

Adis International

Access to resources Recommend Favorite

Can we accurately predict the development of rheumatoid arthritis in the preclinical phase?

By  

Arthritis & Rheumatism, Vol. 48, Iss. 10, 2003-10 ,pp. : 2701-2705

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rheumatoid Arthritis: Strategies in the Management of Patients Showing an Inadequate Response to TNFα Antagonists

By Lutt Joseph R.   Deodhar Atul  

Drugs, Vol. 68, Iss. 5, 2008-01 ,pp. : 591-606

Adis International

Access to resources Recommend Favorite